10 Undervalued European Stocks To Invest In Now
On June 10, Carmine De Franco of BNP Paribas Asset Management appeared on CNBC to talk about the European market.
Author Archive - Noor Ul Ain Rehman
11 Best Drug Stocks to Buy According to Hedge Funds
Health and Human Services Secretary Robert F. Kennedy Jr.
Barclays Lowers Victoria’s Secret & Co. (VSCO) Price Target to $22, Keeps Overweight Rating
On June 5, Barclays analyst Adrienne Yih slashed the firm's price target on Victoria's Secret & Co.
BofA Reiterates Buy Rating on Asana (ASAN), Lowers PT to $21
On June 4, Bank of America Securities analyst Michael Funk reiterated a Buy rating for Asana, Inc. (NYSE:ASAN), reducing the price target to $21 from $23.
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00.
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00.
Truist Financial Maintains Buy Rating on Sixth Street Specialty Lending (TSLX)
Sixth Street Specialty Lending Inc.
DBS Maintains Hold Rating on NIO Inc. (NIO) Stock
On June 5, DBS analyst Rachel Miu maintained a Hold rating on NIO Inc. (NYSE:NIO) and set a price target of HK$38.00.
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4.
BofA Maintains Hold Rating on PVH Corp. (PVH), Sets $86 PT
In a report released on June 4, BofA analyst Christopher Nardone maintained a Hold rating on PVH Corp. (NYSE:PVH) with a price target of $86.00.
Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT
Keith Weiss from Morgan Stanley maintained a Hold rating on Snowflake Inc. (NYSE:SNOW) on June 4, keeping the associated price target at $200.00.
Morgan Stanley Slashes Asana (ASAN) Price Target to $13, Keeps Underweight Rating
The rating update came after the company announced fiscal Q1 2026 results on June 3, with revenue reaching $187.3 million, reflecting a 9% year-over-year growth.
Wells Fargo Remains Bullish on Snowflake (SNOW), Keeps Buy Rating
The analyst based his rating on the company's growth potential and strategic positioning, particularly due to its focus on integrating AI into its product offerings.
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform
On June 3, Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform without a price target.
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock
On June 4, Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte Corporation (NASDAQ:INCY) with a price target of $68.00.
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT
On June 3, Stephens & Co.
Needham Remains Bullish on CrowdStrike (CRWD) Following Q1 Report, Raises Price Target to $530
On June 4, Needham analyst Mike Cikos maintained a bullish stance on CrowdStrike Holdings, Inc.
Stifel Nicolaus Lifts CrowdStrike (CRWD) Price Target to $495, Maintains Buy Rating
On June 4, Stifel Nicolaus analyst Adam Borg maintained a Buy rating on CrowdStrike Holdings, Inc. (NASDAQ:CRWD), lifting the associated price target to $495 from $480.
Goldman Sachs Maintains Sell Rating on Victoria’s Secret (VSCO) Stock
On June 4, Goldman Sachs maintained a Sell rating on Victoria's Secret & Co. (NYSE:VSCO) with a $15 price target.
BofA Maintains Buy Rating on Apple Inc. (AAPL), Keeps PT
On June 2, BofA analyst Wamsi Mohan maintained a Buy rating on Apple Inc. (NASDAQ:AAPL), retaining the associated price target at $235.00.
Barclays Lifts Price Target on Credo Technology Group (CRDO) Following Strong Q4 Report
On June 3, Barclays analyst Tom O’Malley raised the firm’s price target on Credo Technology Group Holding Ltd.
TD Cowen Reiterates Buy Rating on Credo Technology Group (CRDO) After Strong Q4
In a report released on June 3, Joshua Buchalter from TD Cowen reiterated a Buy rating on Credo Technology Group Holding Ltd. (NASDAQ:CRDO) with a price target of $85.00.
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval
The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain tumor types.
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT
The analyst based the rating update on the recent FDA approval of Ojemda (tovorafenib) for BRAF-altered, relapsed, or refractory pediatric low-grade glioma (pLGG).
Wells Fargo Lifts CrowdStrike’s (CRWD) Price Target to $550, Maintains Buy Rating
The rating was issued in anticipation of the company's fiscal Q1 2026 results on June 3, which the analyst expects to show strong growth, suggesting a return to growth in net ...
Morgan Stanley Lifts Pebblebrook Hotel Trust (PEB) PT to $8, Keeps Underweight Rating
The rating update came when the firm raised estimates “modestly across the board” for its Gaming & Lodging coverage to take into account the better Q1 results, along with ...
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO)
In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) with a $3.00 price target.
BofA Slashes Price Target on Cooper Companies (COO), Keeps Buy Rating
On May 30, BofA lowered the firm’s price target on Cooper Companies, Inc.
Morgan Stanley Reiterates Buy Rating on Costco (COST), Sets $1,225 PT
On May 30, Morgan Stanley analyst Simeon Gutman reiterated a Buy rating on Costco Wholesale Corporation (NASDAQ:COST) and set a price target of $1,225.00.
Jefferies Maintains Buy Rating on Costco (COST) After Q3 Report
On May 30, analyst Corey Tarlowe from Jefferies reiterated a Buy rating on Costco Wholesale Corporation (NASDAQ:COST), keeping the price target at $1,180.00.
Wells Fargo Maintains Underweight Rating on Ally Financial (ALLY) Stock
Wells Fargo analyst Donald Fandetti maintained an Underweight rating on Ally Financial Inc. (NYSE:ALLY) with a $32 price target.
BofA Slashes Cooper Companies (COO) Price Target to $96, Keeps Buy Rating
On May 30, BofA analyst Craig Bijou reiterated a Buy rating on Cooper Companies, Inc. (NASDAQ:COO), lowering the associated price target to $96.00 from $120.00.
Cooper Companies (COO) Gets Buy Rating From William Blair Following Q2 Report
On May 30, William Blair analyst Margaret Kaczor maintained a bullish stance on Cooper Companies, Inc.
JPMorgan Downgrades Cooper Companies (COO) to Neutral, Cuts PT
On May 30, JPMorgan downgraded Cooper Companies, Inc. (NASDAQ:COO) to Neutral from Overweight and slashed the price target to $76 from $110.
Jefferies Remains Bullish on Marvell Technology (MRVL) Following Q1 Report
On May 30, Jefferies analyst Blayne Curtis maintained a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a $90.00 price target.
Barclays Lifts GE Vernova’s (GEV) Price Target to $500, Keeps Overweight Rating
The firm updated the rating because it sees a narrowing in end-market growth dispersion.
BofA Maintains Buy Rating on Marvell Technology (MRVL) Stock
On May 30, BofA analyst Vivek Arya reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL), retaining the price target of $72.00.
Benchmark Co. Reiterates Buy Rating on Marvell Technology (MRVL)
On May 30, analyst Cody Acree from Benchmark Co. reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a $95.00 price target.
J.P. Morgan Upgrades Tronox Holdings (TROX) to Overweight, Lifts PT
J.P. Morgan analyst Jeffrey Zekauskas upgraded Tronox Holdings plc (NYSE:TROX) to Overweight from Neutral on May 30, and raised the price target to $7 from $5.
Needham Maintains Buy Rating on Veeva Systems (VEEV), Sets $300 PT
On May 29, Needham analyst Ryan MacDonald reiterated a Buy rating on Veeva Systems Inc. (NYSE:VEEV) and set a price target of $300.00.
Melius Research Lifts Nvidia (NVDA) Price Target After Q1 Report
Melius Research analyst Ben Reitzes reiterated a bullish stance on NVIDIA Corporation (NASDAQ:NVDA), giving it a Buy rating on May 29.
William Blair Remains Bullish on Veeva Systems (VEEV) After Solid Q1
William Blair analyst Dylan Becker maintained a bullish stance on Veeva Systems Inc. (NYSE:VEEV) and gave it a Buy rating on May 29.
Stifel Nicolaus Maintains Buy Rating on Agilent Technologies (A), Sets $151 PT
On May 29, Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Agilent Technologies, Inc. (NYSE:A) and set a price target of $151.00.
BofA Maintains Hold Rating on Agilent Technologies (A) After Q2 Report
On May 29, analyst Michael Ryskin from Bank of America Securities reiterated a Hold rating on Agilent Technologies Inc (NYSE:A) with a $128.00 price target.
Oppenheimer Reiterates Buy Rating on Nvidia (NVDA) After Solid Q1
On May 29, Oppenheimer analyst Rick Schafer reiterated a Buy rating on NVIDIA Corporation (NASDAQ:NVDA) and set a price target of $175.00.
BofA Lifts Coherent Corporation’s (COHR) Price Target to $92.00, Keeps Buy Rating
Arya based the price target increase on the company's potential for significant growth, updating it after COHR's 2025 Analyst and Investor Day on May 28 on which it detailed its...
Oppenheimer Slashes Price Target on Salesforce (CRM), Maintains an Outperform Rating
On May 29, Oppenheimer analyst Brian Schwartz lowered the firm's price target on Salesforce, Inc.
Bernstein Maintains Underperform Rating on Salesforce (CRM)
The rating update followed the company's fiscal Q1 2026 earnings release, which took place on May 28.
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation
The price target decrease followed the company's May 23 announcement stating that its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients failed to meet...
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure
Although the firm is bullish on Prothena Corporation plc (NASDAQ:PRTA), it reduced its price target after the company announced the discontinuation of its Phase 3 AFFIRM-AL clinical...
